Yttrium-90 Radiation for Unresectable Liver Cancer
This study is testing a treatment called TheraSphere® Yttrium-90 microspheres for people with hepatocellular carcinoma (HCC), a type of liver cancer, that cannot be removed by surgery. This treatment involves delivering radiation directly to the tumor. Researchers want to see how well the treatment shrinks the cancer (Objective Response Rate) and if there are any side effects. They will also look at how the treatment affects your quality of life. You might be able to join if you have HCC that is 2-5 cm (centimeters) or 2-3 tumors each 3 cm or less, and you haven't had other treatments for these specific tumors. The study plans to enroll 64 participants.
- Study design
- This is a Phase II study, meaning it's an early-stage study to see if a treatment is effective and safe. It is a single-arm study, so all participants will receive the same treatment. It is also open-label, meaning both you and the study team will know what treatment you are receiving.
- What's involved
- Participants will receive a single administration of TheraSphere® Yttrium-90 microspheres. You will also complete Health Related Quality of Life Questionnaires (HRQOL) and have your cancer response and side effects monitored.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for quality-of-life outcomes and survival for up to 3 years after treatment. Cancer response and side effects will be measured for up to 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma
At a glance
Conditions
NCT07110233
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of California, San Francisco
San Francisco, Californiastudy coordinator listed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Ryan Lokken, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Objective Response Rate (ORR) by mRECISTUp to 6 months
The objective response rate (ORR) after radiation segmentectomy in participants will be evaluated using a modified Response Evaluation Criteria in Solid Tumors (mRECIST) based on the best tumor response where Complete Response (CR) is defined as the disappearance of any intratumoral arterial enhancement in all target lesions, Partial Response (PR) is defined as a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions, Stable Disease (SD) is defined as any cases that do not qualify for either partial response or progressive disease, and Progressive Disease (PD) is defined as an increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started.
- Percentage of participants with treatment-related adverse eventsUp to 6 months
The percentage of participants with grade 3 or greater, treatment-related adverse events as classified by NCI Common Terminology Criteria for Adverse Events (CTCAE) will be reported.